

Melamine: Information for Pediatric Health Professionals

Consumption of melamine-contaminated infant formula has been linked to urinary tract ailments in nearly 300,000 infants and the deaths of six infants in China in 2008. Melamine causes crystalluria which may lead to irritation of the urinary tract epithelium, kidney stones, and acute kidney failure.

QUICK FACTS

- Infant formula manufactured in China and available for purchase at Asian markets in the US could still pose a risk to infants.
- U.S. manufactured formula is considered safe for consumption at this time.
- Infants who recently emigrated from China and have a clinical picture suggestive of melamine-induced nephrotoxicity should be evaluated and referred to a pediatric nephrologist.
- Avoid milk and milk containing products that could originate from China.
- An expert body from the American Society of Pediatric Nephrologists does not recommend testing on asymptomatic infants who may have been living in the areas where infant exposure and disease occurred in China.
- An environmental health consultation can be obtained from a pediatric environmental health specialty unit by calling 888-347-2632 or going to www.pehsu.net

What kinds of food may be contaminated with melamine?

Prior to August 6, 2008 melamine was illegally added to milk in China to fraudulently inflate the protein content. Melamine contaminated milk was used in the manufacture of infant formula and as an ingredient in various dairy products and other foods.

Food produced in China found to have melamine contamination:

- Infant Formula (before Aug 6, 2008)
- Foods with milk-derived ingredients
- Eggs
- Pet Food

The detection of melamine in a variety of human and animal foods suggests that melamine contamination of Chinese food products may still exist. Recent testing of infant formula manufactured in the U.S. has identified only trace concentrations. These are up to 10,000 times lower than concentration in Chinese formula associated with infant illness and ten-fold lower than the FDA acceptable level for melamine in infant formula.

What is melamine?

Melamine is a synthetic compound used in plastic tableware, flame retardants, paper, paperboard, and industrial coatings. Melamine is a metabolite of a pesticide (cryomazine) and a decomposition product of a food equipment sanitizer (trichloromelamine). These are estimated to contribute negligible amounts of melamine to food. Melamine is not approved in the U.S. as a fertilizer, as it is in some other countries, nor is it approved for use in human or animal food.

Why are infants a high risk group for melamine-related health effects?

Infants may consume contaminated formula as their primary food source. Older children and adults who consume a variety of foods will receive less melamine per unit of body weight (i.e. lower dose) from a contaminated source. The smaller lumens of the infant urinary tract, tubules and blood vessels may lead to easier irritation of tubular and urinary tract walls, easier occlusion by uroliths, and proportionately greater compression of blood vessels by urinary stones.

Infants have a lower glomerular filtration rate than older children and adults. This may decrease the flow of urine through the tubules thus predisposing crystals to bump together and co-crystallize. Lastly, it is possible that uric acid may co-crystallize with melamine in infants (Ogasawara 1995). Uric acid is excreted into the urine at a much higher rate in infants relative to older children and adults. The fractional excretion rate of uric acid is 61% in 29-33 week old infants and decreases to 12% at 3-4 years of age (Baldree and Stapleton, 1990).

What are the health effects of ingesting melamine?

Acute

The acute toxicity of melamine is low. In the presence of its analogue and common cocontaminant, cyanuric acid, toxicity is much higher. Both are excreted via the kidneys without metabolism with half-lives estimated to be a few hours. Each may form crystals in urine. When both are present in urine, they can combine as melamine cyanurate complexes. This results in highly insoluble, larger, and more numerous calculi than either of the two chemicals alone. These irritate the urinary tract lining and may lead to obstruction and uremia.

The signs and symptoms of acute melamine exposure (high dose over several days) and presumably in the presence of a co-crystallizing substance, are related to acute urolithiasis or cystitis (e.g. anorexia, hematuria, abdominal pain, oliguria, uremia).

• Chronic

Longer-term exposure (weeks to months or years) to melamine results in the same adverse effects but the presenting signs may be less severe. Animal studies suggest that long-term exposure can also result in urinary tract cancer due to epithelial irritation, and subsequent inflammation, from crystals and stones.

A recent screening survey of 3,170 children in Hong Kong age 12 years of less who consumed low dose melamine containing milk products for at least one month found no severe renal disease; one child had a confirmed stone, 7 had likely melamine-related renal deposits, and less than 1% had microscopic hematuria.

The long-term effects from exposure to melamine and/or cyanuric acid in the asymptomatic child and the long term health consequences of early life melamine related kidney disease are unknown. These are key data gaps that need to be addressed.

What is an appropriate medical evaluation for melamine exposure?

The most important action is to stop any ongoing exposure and continue evaluation based on symptoms.

The need for medical evaluation of asymptomatic but potentially melamine-exposed infants and children, such as those who have recently emigrated from China to the United States, is not clear. Currently, an expert committee from the American Society of Pediatric Nephrologists does not

recommend testing on asymptomatic infants who may have been living in the areas where infant exposure and disease occurred in China (reference below).

While screening tests for renal function in internationally adopted children are not uniformly recommended, a complete physical examination including measurement of blood pressure, assessment of general nutritional status and hydration should be considered. Tests for melamine in blood serum and urine are investigational, not commercially available, and of limited clinical utility given the rapid elimination from the body once exposure has ceased.

Melamine toxicity should be evaluated in any infant or young child with the appearance of urinary system signs or symptoms AND suspected or known exposure to melamine-contaminated formula/food products.

The medical assessment of the affected child might include the following studies:

- renal function test serum electrolytes, urea nitrogen and creatinine
- urinalysis (microscopic evaluation of hematuria)
- renal imaging ultrasound (to rule out obstruction)
- consultation with a pediatric nephrologist for those children in whom melamine exposure and potential renal injury are confirmed.

Recommendations and more detailed information are available from the American Society of Pediatric Nephrologists.

What regulatory actions are being taken?

Using standard and similar risk assessment approaches the food regulatory agencies in Canada, the European Union, Australia / New-Zealand and Hong Kong established a tolerance for melamine in infant formula varying from 0.5 to 2.5 parts per million (ppm). FDA has established a new infant formula tolerance of melamine alone or cyanuric acid alone, at or below 1 ppm. Updates and revisions will continue. For more information on public health reference levels and guidelines, see the resources listed below.

References and Resources for More Information

American Society of Pediatric Nephrologists. Statement: Kidney Disease from Powdered Infant Formula-based Melamine Exposure in Chinese Infants. http://www.aspneph.com/ASPNStatement%20Melamine%20Oct22_cbl%20 (3).pdf

Baldree LA, Stapleton FB. Uric acid metabolism in children. Pediatr Clin North Am 1990; 37:391-418.

Brown CA et al. Brief communications. Outbreaks of renal failure associated with melamine and cyanuric acid in dogs and cats in 2004 and 2007. J Vet Diagn Invest 19:525–531 (2007)

University of Washington Center for Adoption Medicine. Melamine and Chinese adoptees. http://www.adoptmed.org/topics/melamine-and-chinese-adoptions.html

CDC - Melamine in Chinese-Manufactured Infant Formula Oct. 2, 2008 http://wwwn.cdc.gov/travel/contentMelamineChina.aspx

US Food and Drug Administration web page on Melamine Contamination in China – contains a listing of product recalls related to melamine contamination http://www.fda.gov/oc/opacom/hottopics/melamine.html#company

FDA Advisory on Melamine contamination. September 26, 2008 http://www.fda.gov/bbs/topics/NEWS/2008/NEW01891.html

FDA Interim Melamine and Analogues Safety/Risk Assessment May 25, 2007 http://www.cfsan.fda.gov/~dms/melamra.html

FDA Updates Health Information Advisory on Melamine Contamination September 23, 2008. http://www.fda.gov/bbs/topics/news/2008/new01889.html

FDA Update Interim Safety and Risk Assessment of Melamine and its Analogues in Food for Humans. November 28, 2008. http://www.cfsan.fda.gov/~dms/melamra4.html

IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man. Geneva: World Health Organization, International Agency for Research on Cancer. 73: 329-338, 1999 http://monographs.iarc.fr/ENG/Monographs/vol73/mono73-17.pdf

Lam, HS, et al. Renal screening in children after exposure to low dose melamine in Hong Kong: cross sectional study BMJ 2008; 337;a2291.

Ogasawara H, Imaida K, Ishiwata H, et al. Urinary bladder carcinogenesis induced by melamine in F344 male rats: correlation between carcinogenicity and urolith formation. Carcinogenesis 1995; 16:2773-7

WHO Melamine-contamination event, China, September - October 2008 http://www.who.int/foodsafety/fs_management/infosan_events/en/index.htl

World Health Organization. Melamine and Cyanuric acid: Toxicity, Preliminary Risk Assessment and Guidance on Levels in Food 25 September 2008 http://www.who.int/foodsafety/fs_management/Melamine.pdf

Acknowledgement: A. Miodovnik, MD, Mount Sinai Pediatric Environmental Health Specialty Unit. T. Guidotti, MD, MPH, J. Paulson, MD, Mid-Atlantic Center for Children's Health and Environment. J. Lowry, MD, Mid-America Pediatric Environmental Health Specialty Unit. C. Karr, MD, PhD, Northwest Pediatric Environmental Health Specialty Unit. M. Miller, MD, MPH, University of California-San Francisco Pediatric Environmental Health Specialty Unit. A. Woolf, MD, MPH, New England Pediatric Environmental Health Specialty Unit. I. Buka, FRCPC, Misericordia and Stollery Children's Hospital, Canada. Ginger Ellingson, Northwest Pediatric Environmental Health Specialty Unit.

Disclaimer: Based upon interpretation of the current literature, the PEHSU program is providing this guidance for persons who wish to take a precautionary approach to personal decisions, and is not meant to substitute for personal medical consultation with your health care provider.